Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRE11 | P49959 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.40 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517991 | 0.88 | LMNA (0.46) | MRE11CA2L3MBTL1ITGB1ITGA4 | |
| SCHEMBL3517987 | 0.88 | LMNA (0.46) | MRE11CA2L3MBTL1ITGB1ITGA4 | |
| SCHEMBL4490755 | 0.85 | MRE11 (0.43) | MRE11CA2L3MBTL1ITGB1ITGA4 | |
| SCHEMBL15109934 | 0.81 | ACE (0.53) | CA2ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL5144531 | 0.79 | LMNA (0.50) | CA2FPR2ITGB3ITGA2B | |
| SCHEMBL5144526 | 0.79 | LMNA (0.50) | CA2FPR2ITGB3ITGA2B | |
| SCHEMBL14032612 | 0.77 | MRE11 (0.40) | MRE11CA2L3MBTL1 | |
| SCHEMBL3520496 | 0.76 | CPB2 (0.49) | MRE11L3MBTL1 | |
| SCHEMBL3520494 | 0.76 | CPB2 (0.49) | MRE11L3MBTL1 | |
| SCHEMBL6779095 | 0.76 | CA2 (0.41) | MRE11CA2FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | MRE11 2106/4885CA2 972/4885TSHR 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.